{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:49:04Z","timestamp":1790246944990,"version":"4.1.0"},"reference-count":59,"publisher":"Impact Journals, LLC","issue":"46","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,15]]},"DOI":"10.18632\/oncotarget.12488","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T07:29:47Z","timestamp":1475738987000},"page":"75954-75967","source":"Crossref","is-referenced-by-count":42,"title":["Doxycycline is an NF-\u03baB inhibitor that induces apoptotic cell death in malignant T-cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Carolina V.","family":"Alexander-Savino","sequence":"first","affiliation":[{"name":"Rochester General Hospital Research Institute, Center for Cancer and Blood Disorders, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Hayden","sequence":"additional","affiliation":[{"name":"Rochester General Hospital Research Institute, Center for Cancer and Blood Disorders, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Richardson","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, University of Rochester School of Medicine, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biomedical Genetics, University of Rochester School of Medicine, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Poligone","sequence":"additional","affiliation":[{"name":"Rochester General Hospital Research Institute, Center for Cancer and Blood Disorders, Rochester, NY, USA"},{"name":"Rochester Skin Lymphoma Center, Fairport, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,6]]},"reference":[{"key":"1","volume-title":"Non-Hodkin's Lymphoma: Incidence Rates, and APC, Lymphoma Subtypes","author":"The Surveillance E, and End Results (SEER) Program","year":"2015"},{"key":"2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Ranki","year":"2007","journal-title":"Blood"},{"key":"3","first-page":"857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and s\u00e9zary syndrome: Clinical prognostic factors and risk for disease progression","volume":"139","author":"Hoppe","year":"2003","journal-title":"Archives of Dermatology"},{"key":"4","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1002\/cncr.27627","article-title":"Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides","volume":"118","author":"Bernengo","year":"2012","journal-title":"Cancer"},{"key":"5","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/bjd.12909","article-title":"Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now?","volume":"170","author":"Quaglino","year":"2014","journal-title":"The British journal of dermatology"},{"key":"6","first-page":"117ra7","article-title":"Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients","volume":"4","author":"Kupper","year":"2012","journal-title":"Sci Transl Med"},{"key":"7","first-page":"10","article-title":"Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors","volume":"2012","author":"Karagiannis","year":"2012","journal-title":"Lymphoma"},{"key":"8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/10428194.2012.720372","article-title":"Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma","volume":"54","author":"Prince","year":"2013","journal-title":"Leukemia & lymphoma"},{"key":"9","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Yocum","year":"2001","journal-title":"Journal of clinical oncology"},{"key":"10","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Duvic","year":"2012","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Kim","year":"2010","journal-title":"Journal of clinical oncology"},{"key":"12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy","volume":"125","author":"Prince","year":"2015","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14656560902895715","article-title":"Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma","volume":"10","author":"Densmore","year":"2009","journal-title":"Expert opinion on pharmacotherapy"},{"key":"14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nrc2044","article-title":"The Connectivity Map: a new tool for biomedical research","volume":"7","author":"Lamb","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"15","first-page":"1","article-title":"The NF-kappaB family of transcription factors and its regulation","volume":"1","author":"Ghosh","year":"2009","journal-title":"Cold Spring Harbor perspectives in biology"},{"key":"16","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive Nuclear Factor \u03baB Activity Is Required for Survival of Activated B Cell-like Diffuse Large B Cell Lymphoma Cells","volume":"194","author":"Staudt","year":"2001","journal-title":"The Journal of Experimental Medicine"},{"key":"17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a000141","article-title":"NF-\u03baB as a Critical Link Between Inflammation and Cancer","volume":"1","author":"Karin","year":"2009","journal-title":"Cold Spring Harbor perspectives in biology"},{"key":"18","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2005-06-2536","article-title":"Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis","volume":"107","author":"Michel","year":"2006","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1084\/jem.20021610","article-title":"Combined Deficiency of p50 and cRel in CD4+ T Cells Reveals an Essential Requirement for Nuclear Factor \u03baB in Regulating Mature T Cell Survival andFunction","volume":"197","author":"Beg","year":"2003","journal-title":"The Journal of Experimental Medicine"},{"key":"20","doi-asserted-by":"publisher","first-page":"14796","DOI":"10.18632\/oncotarget.4193","article-title":"Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline","volume":"6","author":"Shapiro","year":"2015","journal-title":"Oncotarget"},{"key":"21","first-page":"165","article-title":"Pharmacokinetic properties of doxycycline in man","author":"Schach von Wittenau","year":"1967","journal-title":"Fifth International Congress of Chemotherapy Proceedings"},{"key":"22","doi-asserted-by":"crossref","first-page":"C539","DOI":"10.1152\/ajpcell.00047.2010","article-title":"Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature","volume":"299","author":"Villarreal","year":"2010","journal-title":"American journal of physiology Cell physiology"},{"key":"23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/138955712798868977","article-title":"Tetracyclines: drugs with huge therapeutic potential","volume":"12","author":"Pourgholami","year":"2012","journal-title":"Mini Rev Med Chem"},{"key":"24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.phrs.2010.10.003","article-title":"Introduction and background","volume":"63","author":"Golub","year":"2011","journal-title":"Pharmacological research"},{"key":"25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.phrs.2010.12.003","article-title":"Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD)","volume":"63","author":"Ryan","year":"2011","journal-title":"Pharmacological research"},{"key":"26","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1001\/jama.297.20.2264","article-title":"Treatment of malaria in the united states: A systematic review","volume":"297","author":"Parise","year":"2007","journal-title":"JAMA"},{"key":"27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00128071-200405050-00005","article-title":"Management of Bullous Pemphigoid","volume":"5","author":"Khumalo","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"28","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: A systematic review","volume":"27","author":"Leyden","year":"2005","journal-title":"Clinical Therapeutics"},{"key":"29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.immunol.14.1.649","article-title":"The NF-kappa B, I kappa B proteins: new discoveries and insights","volume":"14","author":"Baldwin","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.16.1.225","article-title":"NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses","volume":"16","author":"Kopp","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"31","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1101\/gad.1228704","article-title":"Signaling to NF-kappaB","volume":"18","author":"Ghosh","year":"2004","journal-title":"Genes Dev"},{"key":"32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Pasqualucci","year":"2009","journal-title":"Nature"},{"key":"33","first-page":"406","article-title":"HTLV tax: a fascinating multifunctional co-regulator of viral and cellular pathways","volume":"3","author":"Kashanchi","year":"2012","journal-title":"Frontiers in microbiology"},{"key":"34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: A Review of Programmed Cell Death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicologic Pathology"},{"key":"35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrc776","article-title":"Death and anti-death: tumour resistance to apoptosis","volume":"2","author":"Krammer","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1152\/nips.01519.2004","article-title":"Morphological Features of Cell Death","volume":"19","author":"Groscurth","year":"2004","journal-title":"Physiology"},{"key":"37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cellsig.2003.08.007","article-title":"Death receptor-induced cell killing","volume":"16","author":"Thorburn","year":"2004","journal-title":"Cellular Signalling"},{"key":"38","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1242\/jcs.114.20.3771","article-title":"Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis","volume":"114","author":"Poirier","year":"2001","journal-title":"J Cell Sci"},{"key":"39","doi-asserted-by":"crossref","first-page":"9357","DOI":"10.1074\/jbc.273.16.9357","article-title":"Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis","volume":"273","author":"Porter","year":"1998","journal-title":"Journal of Biological Chemistry"},{"key":"40","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.275.5303.1129","article-title":"Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked","volume":"275","author":"Wang","year":"1997","journal-title":"Science"},{"key":"41","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1038\/sj.onc.1204926","article-title":"Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer","volume":"20","author":"Johnson","year":"2001","journal-title":"Oncogene"},{"key":"42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0560.1995.tb00733.x","article-title":"Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates","volume":"22","author":"Wood","year":"1995","journal-title":"Journal of cutaneous pathology"},{"key":"43","first-page":"249","volume-title":"Skin Cancer: Basic Science, Clinical Research and Treatment","author":"Orfanos","year":"1995"},{"key":"44","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0344-0338(11)80423-1","article-title":"Mycosis fungoides: Expression of C-myc p62 p53, bcl-2 and PCNA Proteins and Absence of Association with Epstein-Barr Virus","volume":"190","author":"Tosca","year":"1994","journal-title":"Pathology - Research and Practice"},{"key":"45","first-page":"69","article-title":"The NF-kappaB-mediated control of ROS and JNK signaling","volume":"21","author":"Franzoso","year":"2006","journal-title":"Histol Histopathol"},{"key":"46","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cell.2004.12.041","article-title":"Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases","volume":"120","author":"Karin","year":"2005","journal-title":"Cell"},{"key":"47","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1158\/0008-5472.CAN-08-3221","article-title":"Inhibition of Constitutively Activated Nuclear Factor-\u03baB Induces Reactive Oxygen Species- and Iron-Dependent Cell Death in Cutaneous T-Cell Lymphoma","volume":"69","author":"G\u00fclow","year":"2009","journal-title":"Cancer Research"},{"key":"48","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.18632\/oncotarget.3174","article-title":"Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease","volume":"6","author":"Lisanti","year":"2015","journal-title":"Oncotarget"},{"key":"49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1113\/jphysiol.2003.049478","article-title":"Mitochondrial formation of reactive oxygen species","volume":"552","author":"Turrens","year":"2003","journal-title":"The Journal of Physiology"},{"key":"50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1042\/bj2420103","article-title":"The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages","volume":"242","author":"Jones","year":"1987","journal-title":"Biochemical Journal"},{"key":"51","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1089\/08892220050193001","article-title":"Activation of I-\u03ba B Kinase by the HTLV Type 1 Tax Protein: Mechanistic Insights into the Adaptor Function of IKK\u03b3","volume":"16","author":"Good","year":"2000","journal-title":"AIDS research and human retroviruses"},{"key":"52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0300-9084(02)01369-X","article-title":"Mitochondrial reactive oxygen species in cell death signaling","volume":"84","author":"Vayssiere","year":"2002","journal-title":"Biochimie"},{"key":"53","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1001\/jamadermatol.2013.4162","article-title":"Primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoma: temporary remission by oral doxycycline","volume":"149","author":"Hadaschik","year":"2013","journal-title":"JAMA dermatology"},{"key":"54","doi-asserted-by":"publisher","first-page":"19336","DOI":"10.18632\/oncotarget.5111","article-title":"Doxycycline: new tricks for an old drug","volume":"6","author":"Kennedy","year":"2015","journal-title":"Oncotarget"},{"key":"55","doi-asserted-by":"publisher","first-page":"14777","DOI":"10.18632\/oncotarget.4401","article-title":"Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells","volume":"6","author":"Sotgia","year":"2015","journal-title":"Oncotarget"},{"key":"56","doi-asserted-by":"publisher","first-page":"14005","DOI":"10.18632\/oncotarget.4159","article-title":"Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy","volume":"6","author":"Lisanti","year":"2015","journal-title":"Oncotarget"},{"key":"57","doi-asserted-by":"publisher","first-page":"35157","DOI":"10.18632\/oncotarget.6038","article-title":"Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil","volume":"6","author":"Jia","year":"2015","journal-title":"Oncotarget"},{"key":"58","doi-asserted-by":"publisher","first-page":"40667","DOI":"10.18632\/oncotarget.5842","article-title":"Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells","volume":"6","author":"Sun","year":"2015","journal-title":"Oncotarget"},{"key":"59","unstructured":"Poligone. Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma (CTCL). 2015. ClinicalTrialsgov."}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T20:50:37Z","timestamp":1657399837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":59,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2016,11,15]]}},"alternative-id":["12488","27732942"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12488","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,6]]}}}